<DOC>
	<DOCNO>NCT00291655</DOCNO>
	<brief_summary>For ethical reason give opportunity adult subject ( ≥16 18 year ) suffer newly diagnose epilepsy complete therapeutic confirmatory , open-label trial N01175 ( NCT00175903 ) conduct levetiracetam monotherapy benefit treatment , receive treatment levetiracetam monotherapy indication levetiracetam grant Europe . To continue assess safety levetiracetam per adverse event report observation weight change .</brief_summary>
	<brief_title>Follow Trial Keppra ( Levetiracetam ) Monotherapy Patients With Newly Diagnosed Epilepsy Coming From N01175 ( NCT00175903 ) .</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Male/female adult subject ( ≥ 16 18 year ) Diagnosis epilepsy ( type seizure may include ) Subjects complete N01175 ( NCT00175903 ) trial benefit levetiracetam monotherapy Other inclusion criterion may apply Subjects withdrawn N01175 ( NCT00175903 ) trial reason Subjects receive treatment levetiracetam N01175 ( NCT00175903 ) trial Subject require addon antiepileptic treatment Subjects country levetiracetam authorize use monotherapy epilepsy treatment Sexually active woman childbearing potential use medically accept birth control method</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>NEWLY DIAGNOSED EPILEPSY</keyword>
	<keyword>LEVETIRACETAM</keyword>
	<keyword>KEPPRA</keyword>
	<keyword>N01175 ( NCT00175903 )</keyword>
</DOC>